Browse > Article

The Differentiation of Malignant and Benign Musculoskeletal Tumors by F-18 FDG PET/CT Studies - Determination of maxSUV by Analysis of ROC Curve  

Kong, Eun-Jung (Departments of Nuclear Medicine, Yeungnam University College of Medicine)
Cho, Ihn-Ho (Departments of Nuclear Medicine, Yeungnam University College of Medicine)
Chun, Kyung-Ah (Departments of Nuclear Medicine, Yeungnam University College of Medicine)
Won, Kyu-Chang (Departments of Endocrinology, Yeungnam University College of Medicine)
Lee, Hyung-Woo (Departments of Endocrinology, Yeungnam University College of Medicine)
Choi, Jun-Heok (Departments of Pathology, Yeungnam University College of Medicine)
Shin, Duk-Seop (Departments of Orthopedics, Yeungnam University College of Medicine)
Publication Information
Nuclear Medicine and Molecular Imaging / v.41, no.6, 2007 , pp. 553-560 More about this Journal
Abstract
Purpose: We evaluated the standard uptake value (SUV) of F-18 FDG at PET/CT for differentiation of benign from malignant tumor in primary musculoskeletal tumors. Materials and Methods: Forty-six tumors (11 benign and 12 malignant soft tissue tumors, 9 benign and 14 malignant bone tumors) were examined with F-18 FDG PET/CT (Discovery ST, GE) prior to tissue diagnosis. The maxSUV(maximum value of SUV) were calculated and compared between benign and malignant lesions. The lesion analysis was based on the transverse whole body image. The maxSUV with cutoff of 4.1 was used in distinguishing benign from malignant soft tissue tumor and 3.05 was used in bone tumor by ROC curve. Results: There was a statistically significant difference in maxSUV between benign (n=11; maxSUV $3.4{\pm}3.2$) and malignant (n=12; maxSUV $14.8{\pm}12.2$) lesions in soft tissue tumor (p=0.001). Between benign bone tumor (n=9; maxSUV $5.4{\pm}4.0$) and malignant bone tumor (n=14; maxSUV $7.3{\pm}3.2$), there was not a significant difference in maxSUV. The sensitivity and specificity for differentiating malignant from benign soft tissue tumor was 83% and 91%, respectively. There were four false positive malignant bone tumor cases to include fibrous dysplasia, Langerhans-cell histiocytosis (n=2) and osteoid osteoma. Also, one false positive case of malignant soft tissue tumor was nodular fasciitis. Conclusion: The maxSUV was useful for differentiation of benign from malignant lesion in primary soft tissue tumors. In bone tumor, the low maxSUV correlated well with benign lesions but high maxSUV did not always mean malignancy.
Keywords
F-18 FDG; PET/CT; bone neoplasm; soft tissue neoplasm; sarcoma;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Schwarzbach M, Dimitrakopoulou-Strauss A, Willeke F, Hinz U, Strauss LG, Zhang YM, et al. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. ANN Surg 2000;231:380-6   DOI   ScienceOn
2 Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, Wu H, Burger C, Bernd L, et al. The role of quantitative $^{18}$F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002;43:510-8
3 Aoki J, Endo K, Watanabe H, Shinozaki T, Yanagawa T, Ahmed AR, et al. FDG-PET for evaluation musculoskeletal tumors. J Orthop Sci 2003;8:435-41   DOI
4 Kole AC, Nieweg OE, Hoekstra HJ, van Horn JR, Koops HS, Vaalburg W. Fluorine-18 fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998;39:810-5
5 Eary J, Conard EU. PET imaging : Update on sarcomas. Oncology 2007;21:249-52
6 Bastiaannet E, Groen H, Jager PL, Cobben DC, van der Graaf WT, Vaalburg W et al. The value of FDG -PET in the detection, grading and response to therapy of soft tissue and bone sarcoma; a systematic review and meta- analysis. cancer treatmemt reviews 2004;30:83-101   DOI   ScienceOn
7 Dehdashti F, Siegel BA, Griffeth LK, Fusselman MJ, Trsk DD, McGuire AH, et al. Benign versus Malignant Intraosseous Lesions : Discrimination by Means of PET with 2- [F-18] fluoro-2-deoxy- D-glucose. Radiology 1996;200:243-7   DOI
8 Ioannidis JPA, Lau J. 18F- FDG PET for the Diagnosis and Grading of Soft Tissue sarcoma: A Meta-Analysis. J Nucl Med 2003;44:717-24
9 Lee SM. Nodular fasciitis mimicking malignant tumor in F-18 FDG PET/CT. Korean J Nucl Med 2005;39:263-5
10 Hamada K, Ueda T, Higuchi I, Inoue A, Tamai N, Myoi A, et al. Peripheral nerve schwannoma: two cases exhibiting increased FDG uptake inearly and delayed PET imaging. Skeletal Radiol 2005; 34:52-7   DOI
11 Ahmed AR, Watanabe H, Aoki J, Shinozaki T, Takagishi K. Schwannoma of the extremities: the role of PET in preoperative planning. Eur J Nucl Med 2001;28:1541-51   DOI
12 Hawkins DS, Schuetze SM, Butrynski JE, Rajendran JG, Vernon CB, Conrad EU, et al. [18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors. J Clin Oncol 2005;23:8828-34   DOI   ScienceOn
13 Kubota K, Kubota R, Yamada S. FDG accumulation in tumor tissue (editorial). J Nucl Med 1993;34:419-21
14 Raisz LG, Rodan GA, Cellular basis for bone turn over. In: Avioli LV, Krane SM, eds. Metabolic bone disease and clinically related disorders. 2nd ed. Philadephia: Saunders; 1990. P. 1-41
15 Chae HL, Park YH. F-18 FDG uptake in the nidus of an osteoid osteoma. Clin nucl med 2007;32:628-30   DOI   ScienceOn
16 Folpe AL, Lyles RH, Sprouse JT, ConradIII EU, Eary JF. (F-18) Florodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;287:1279-87
17 Dahlin DC, Unni KK Bone tumors:general aspects and data on 8542 cases. 4th ed. Springfield: Thomas; 1986. p. 413-20
18 Schwarzbach M, Hinz U, Strauss LG, Willeke F, Cardona S, Mechtersheimer G, et al. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. ANN Surg 2005;241:286-94   DOI   ScienceOn
19 Fujimoto R, Higashi T, Nakamoto Y, Hara T, Lyshchik A, Ishizu K et al. Diagnostic accuracy of bone metastases detection in cancer patients : comparison between bone scintigraphy and whole body FDG-PET. Ann Nucl Med 2006;20:399-408   DOI
20 Ogose A, Hotta T, Morita T, Yamammura S, Hosaka N, Kobayashi H, et al. Tumors of peripheral nerves: correlation of symptom, clinical signs, imaging features, and histologic diagnosis. Skeletal Radiol 1999;28:183-8   DOI
21 Jadvar H, Gamie S, Ramanna L, Conti PS. Musculoskeletal system. Semin Nucl Med 2004;34:254-261   DOI   ScienceOn
22 Griffeeth LK, Dehdashti F, McGuire AH, McGuire DJ, Perry DJ, Moerlein SM, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro - 2 - deoxy - D - glucose. Radiology 1992;182: 185-94   DOI
23 Gilkey FW, Moser RP. The biology of cartilage. ed. Philadelphia: Hanley and Belfus; 1990. p. 1-7
24 Aoki J , Watanabe H, Shinozaki T, Takagishi K, Ishihima H, Oya N, et al. FDG PET of primary benign and malignant bone tumors : standard uptake value of 52 lesions. Radiology 2001;219:774-7   DOI
25 Ling L, Klein MJ, Sissons HA, Steiner GC, Winchester RJ. Expression of Ia and monocyte and macrophages lineage antigens in giant cell tumor of bone and related lesions. Arch Pathol Lab Med 1988;112:65-9
26 Watanabe H, Shinozaki T, Yanagawa T, Aoki J, Tokunaga M, Inoue T, et al. Glucose metabolic analysis of musculoskeletal tumours using $^{18}$fluorine-FDG PET as an aid to preoperative planning. J Bone Joint Surg Br 2000;82:760-7   DOI
27 Magnani P, Thomas TP, Tennekon G, De Vries GH, Greene DA, Brosiu FC III. Regulation of glucose transport in cultured Schwann cells. J Peripheral nerve Syst 1998;25:589-92
28 Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F] fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33: 683-91   DOI
29 Cancer Incidence in Five Continents Vol. 8. International Agency for Research on Cancer Web site. http://www-dep.iarc.fr/CI5_original/ table2.asp?cancer=170&volume=8&sex=1&age_from=1&age_to=18& submit=Execute. html. Updated May 2007. Accessed August 15, 2007
30 Johnston J. Giant cell tumor of bone: the role of the giant cell in orthopedic pathology. Orthop Clin North Am 1977;8:751-70
31 Balint E, Szabo P, Marshall CF, Sprague SM. Glucose-induced inhibition of in vitro bone mineralization. Bone 2001;28:21-8   DOI   ScienceOn
32 Schulte M, Brecht -Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med. 2000;41:1695-701
33 Ferner RE, Lucas JD, O'Doherty MJ, Hughes RA, Smith MA, Cronin BF, et al. Evaluation of 18-fluorodeoxyglucose positron emission tomography (18FDG-PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis. J Neurol Neurosurg Psychiatry 2000;68:353-7   DOI
34 Vinay Kumar, Abul K. Abbas, Nelson Fausto. Robbins and Cotran Pathologic basis of disease 7th ed. Philadelphia, Pa. : Elsevier Saunders, 2005;p1273-324
35 Gyorke T, Zajic T, Lange A, Schafer O, Moser E, Mako E, et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun 2006;27:17-24   DOI   ScienceOn